Navigation Links
Metabolex Initiates Phase 2 Trial of Arhalofenate
Date:5/19/2011

HAYWARD, Calif., May 19, 2011 /PRNewswire/ -- Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, announced today that it has initiated a Phase 2 clinical trial of arhalofenate (MBX-102), its product candidate for the management of hyperuricemia in patients with gout.

This randomized, double-blind, placebo-controlled study will evaluate the safety and urate-lowering activity of 400 and 600 mg of arhalofenate in 60 patients with hyperuricemia and a diagnosis of gout. The primary endpoint of the study is the percent reduction in serum uric acid levels from baseline following four weeks of treatment. As part of its broader Phase 2 program, Metabolex will also be initiating a combination study with allopurinol in patients refractory to allopurinol and a combination study with febuxostat (Uloric®, Takeda Pharmaceutical Company Limited; Adenuric®, Ipsen and Menarini).

Arhalofenate is a novel, orally administered, small molecule uricosuric agent that was previously under development by Metabolex for Type 2 diabetes. Arhalofenate has completed eight Phase 1 and four Phase 2 studies which demonstrate that it has excellent safety and tolerability in more than 550 patients for up to six months of treatment. During this development program, it was observed that once daily dosing with arhalofenate not only lowers glucose and triglycerides, but also results in robust, dose-dependent reductions in serum uric acid through its uricosuric activity. The uric acid reductions were fully retained in patients with mild-to-moderate renal insufficiency. Thus, arhalofenate is a potential best-in-class uricosuric agent that not only corrects the hyperuricemia associated with gout, but also addresses other aspects of metabolic syndrome seen in patients with gout.

"We are excited about initiating our gout trials. Our Phase 2 program is designed to show that arhalofenate has a broad clinical profile for the treatment of hyperuricemia and gout including first-line use and, for patients not reaching treatment goals, in combination with allopurinol or febuxostat," said Harold Van Wart, President and CEO of Metabolex. "Advancing the development of arhalofenate has the potential to significantly improve the lives of patients suffering from gout."

About Hyperuricemia and Gout

Gout is a chronic, progressive rheumatic disease, caused by an inflammatory response to uric acid crystals deposited in joints and soft tissues as a result of excess uric acid in the blood (hyperuricemia). Elevated sUA levels cause urate crystals to form in joints triggering acute arthritic flares, chronic destructive arthropathy and formation of tophi. According to the NHANES (2007-2008) study, the incidence of hyperuricemia in the US is over 45 million and over eight million have progressed to a gout diagnosis.

About Metabolex

Metabolex is a privately-held biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases. The company has three clinical-stage compounds: Arhalofenate, which has completed four Phase 2 trials and is currently enrolling patients in a Phase 2 trial for gout; MBX-2982, which has recently completed a Phase 2a trial in Type 2 diabetics; and MBX-8025, which has completed a Phase 2 trial in patients with dyslipidemia.

For additional information about Metabolex and its development pipeline, visit www.metabolex.com.

Contact:
Donald Hill
Metabolex, Inc.
(510) 293-8800
dhill@metabolex.com


'/>"/>
SOURCE Metabolex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Metabolex Announces Election of Kurt von Emster to Board of Directors
2. Metabolex Announces Positive Results From Phase 1a Clinical Trial of MBX-2982
3. Two Metabolex Projects Recognized in Windhovers Top 10 Lists for Partnering Opportunities
4. Isis Initiates Phase 1 Study of ISIS-TTRRx and Earns $5 Million Milestone Payment From GlaxoSmithKline
5. TissueGene Initiates Patient Enrollment for a Phase II Study of TG-C for Osteoarthritis of the Knee
6. Proteon Therapeutics Initiates Patient Enrollment in Phase 2 Clinical Study of PRT-201 in Hemodialysis Patients
7. S*BIO Initiates Phase 2 Clinical Trial of its Novel JAK2 Inhibitor SB1518 in North America for Advanced Lymphoid Malignancies
8. Stephens Initiates Coverage on Vermillion
9. Cell Therapeutics Initiates Pixantrone PIX-R Pivotal Trial for Treatment of Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
10. American Regent Initiates Voluntary Nationwide Recall of Dexamethasone Sodium Phosphate Injection, USP, 4 mg/mL, 1 mL Single Dose Vials; 5 mL and 30 mL Multiple Dose Vials
11. CalciMedica Initiates Phase I Clinical Trial of First CRAC Channel Inhibitor (CCI) for Psoriasis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... TORONTO , June 23, 2016 /PRNewswire/ - ... Ontario biotechnology company, Propellon ... the development and commercialization of a portfolio of ... cancers. Epigenetic targets such as WDR5 represent an ... contribute significantly in precision medicine for cancer patients. ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... and Mold) microbial test has received AOAC Research Institute approval 061601. , “This ... introduced last year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. ...
(Date:6/23/2016)... 23, 2016   EpiBiome , a precision microbiome ... in debt financing from Silicon Valley Bank (SVB). The ... to advance its drug development efforts, as well as ... "SVB has been an incredible strategic partner to ... traditional bank would provide," said Dr. Aeron Tynes ...
(Date:6/23/2016)... ... 23, 2016 , ... In a new case report published today in STEM ... who developed lymphedema after being treated for breast cancer benefitted from an injection of ... dealing with this debilitating, frequent side effect of cancer treatment. , Lymphedema ...
Breaking Biology Technology:
(Date:6/21/2016)... 21, 2016 NuData Security announced today that ... of principal product architect and that Jon ... customer development. Both will report directly to ... moves reflect NuData,s strategic growth in its product ... customer demand and customer focus values. ...
(Date:6/15/2016)... York , June 15, 2016 ... new market report titled "Gesture Recognition Market by Application ... Forecast, 2016 - 2024". According to the report, the  ... 11.60 billion in 2015 and is estimated to ... USD 48.56 billion by 2024.  Increasing ...
(Date:6/7/2016)... 7, 2016  Syngrafii Inc. and San Antonio ... that includes integrating Syngrafii,s patented LongPen™ eSignature "Wet" ... collaboration will result in greater convenience for SACU ... while maintaining existing document workflow and compliance requirements. ... Highlights: ...
Breaking Biology News(10 mins):